Global expansion US Pharma Lab operates with a broad manufacturing footprint across the United States and China, is NSF cGMP-certified and US FDA-audited, and is now part of Biofarma Group, signaling access to an expanded global network and potential cross-market opportunities for contract manufacturing, formulation services, and packaging collaborations.

Strategic acquisition Acquisition by Biofarma Group in 2023 situates US Pharma Lab within a larger CDMO ecosystem with eight manufacturing sites and a diversified product focus, creating upsell opportunities for integrated services such as development, manufacturing, and packaging for cosmetics, probiotic drugs, food supplements, and medical devices.

Nutraceutical focus Strong positioning in nutraceutical quality, consistency, and innovation presents a clear doorway for selling advanced development services, high-potency formulations, and regulatory-compliant sourcing to partners seeking reliable supplement manufacturing and white-label capabilities.

Tech-enabled ops Adoption of tools like SYSPRO, Power BI, and other enterprise systems indicates mature manufacturing operations; this supports conversations around scalable production capacity, traceability, and data-driven quality assurance to potential clients seeking compliant CDMO support at scale.

Financial and market leverage Revenue in the mid-range of hundreds of millions positions US Pharma Lab as a credible partner for mid-market to upper-mid-market collaborations; potential sellers’ due diligence and partnership pitches can emphasize stability, global reach, and access to Biofarma’s international footprint to attract larger-volume collaborations.